Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446940 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
A Phase 2 study of Hepatitis C, sponsored by Bader, Ted, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00446940: Completed Phase 2 study of Hepatitis C, sponsored by Bader, Ted, M.D..
NCT00446940 is a Phase 2 study of Hepatitis C that has completed, run by Bader, Ted, M.D.. The registered enrollment target is 16 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00446940, a Phase 2 study of Hepatitis C, has completed, sponsored by Bader, Ted, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.
Conditions Studied
Interventions
- DRUG rosuvastatin
- DRUG atorvastatin
Study Locations (1)
Oklahoma
- VA Hospital - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00446940 record still lists
NCT00446940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which rosuvastatin is the first listed.
NCT00446940 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00446940 about?
NCT00446940 is a clinical study titled "Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C". Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.
What is the current status of trial NCT00446940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-12. Estimated completion is 2007-03.
What conditions does trial NCT00446940 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00446940?
The interventions under investigation include: rosuvastatin (DRUG), atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00446940?
This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00446940 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00446940's enrollment target sits among peer trials
16 100th of 106 higher than 7 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
-
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia